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Summary at a Glance: 
 
 
We evaluated the 4 metre gait speed (4MGS), a simple functional performance test, in people 
with stable IPF. We found 4MGS a reliable, valid and responsive measure that can detect a 
patient phenotype with worse dyspnoea, exercise performance, quality of life and prognostic 
risk. 
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ABSTRACT 
 
Background and objective: Usual gait speed over four metres (4MGS) is an established 
functional performance measure in older adults that consistently predicts adverse health outcomes, 
but few data exist in idiopathic pulmonary fibrosis (IPF). We assessed the reliability of 4MGS, its 
relationship with established outcome measures, and its responsiveness to pulmonary 
rehabilitation. 
Methods: In four prospective IPF cohorts, 4MGS inter-observer (n=46) and test-retest (n=46) 
reliability, concurrent validity (n=65 and n=62) and responsiveness (n=60) were determined. The 
phenotypic characteristics of all patients stratified according to slow 4MGS (<0.8ms-1) were 
compared, including lung function parameters, high-resolution computed tomography (HRCT) of 
the chest, six minute walk test distance (6MWD), Medical Respiratory Council (MRC) Dyspnoea 
score, King's Brief Interstitial Lung Disease (KBILD) questionnaire and Gender Age Physiology 
(GAP) prognostic index. 
Results: Intra-class correlation coefficients for inter-observer and test-retest reliability were 0.996 
and 0.983 respectively. There was a strong association between 4MGS and 6MWD (r=0.76; 
p<0.0001) and moderate correlations with MRC (r=-0.56), KBILD (r=0.44) and GAP index (r=-
0.41); all p<0.005. 4MGS improved significantly with pulmonary rehabilitation (mean (95% 
confidence interval) change: 0.16 (0.12 to 0.20) ms-1, effect size 0.65. Patients with slow 4MGS 
had significantly worse exercise performance (6MWD: -167 (-220 to -133)m), dyspnoea, health 
status and prognosis index than those with preserved 4MGS, despite similar lung function and 
HRCT parameters.   
Conclusion: 4MGS is a simple, reliable, valid and responsive tool that may detect a patient 
phenotype with worse exercise performance, dyspnoea, health status and prognosis index in stable 
IPF. 
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INTRODUCTION  
 
Idiopathic pulmonary fibrosis (IPF), a disease of older people, is a progressive fibrosing lung 
condition with a median survival of 2.8 to 4.2 years.1  It is increasingly recognised that ageing and 
related extra-pulmonary manifestations, such as muscle dysfunction, depression and 
cardiovascular disease, contribute to morbidity in IPF.2 There is growing interest in assessment 
tools outside of lung function and thoracic imaging that reflect these aspects. Due to the 
progressive nature of IPF, these tools should be feasible and reproducible in relevant healthcare 
environments, from the clinic to the hospital bedside, home and palliative care settings, and 
acceptable to those with severe exertional dyspnoea.  
4 metre gait speed (4MGS), a measure of usual walking speed, is widely used in gerontology as a 
measure of functional and lower limb performance,3 and a surrogate marker of sarcopenia and 
frailty.4 It has been consistently shown to be an independent predictor of physical and cognitive 
disability, falls, hospitalisation and mortality in community-dwelling elders,3, 5, 6 and is often 
described as a ‘vital sign’ or indicator of ‘multi-system well-being’.5, 7  4MGS has been shown to 
be feasible in home,8 acute hospital,9 and outpatient settings.10  In older adults, slow gait speed is 
defined as <0.8 ms−1,11, 12 corresponding to a reduction in median life expectancy.12  
The relevance of 4MGS to chronic respiratory disease has not been fully realised, with studies 
largely confined to chronic obstructive pulmonary disease9, 10, 13, 14 or acute respiratory distress 
syndrome.15  To date no studies have examined 4MGS in an IPF-specific population, but three 
have evaluated gait speed in interstitial lung disease (ILD) patients.16-18 Significant associations 
between 4MGS and measures of dyspnoea and exercise capacity were reported in people with 
chronic lung disease (n=55 ILD)16 and ILD,18 and 4MGS was shown figuratively to improve post-
pulmonary rehabilitation (PR) in ILD patients but absolute data was not reported which renders 
interpretation difficult.18 Furthermore, in one study gait speed was measured over 2.4 metres17 a 
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distance which is not sufficiently long to ensure measurement accuracy or satisfactory test-retest 
reliability.19, 20  Accordingly, we hypothesised that 4MGS may be a useful assessment tool in IPF. 
The aims of the study were to: 1) determine the reliability, concurrent validity and responsiveness 
of 4MGS in IPF; 2) describe the phenotypic characteristics of IPF patients and “slow” 4MGS.  
METHODS 
 
Study participants  
 
Participants were prospectively recruited from outpatient respiratory, ambulatory oxygen and PR 
clinics at the Royal Brompton and Harefield Hospitals, UK between January and December 2015. 
We included people diagnosed with IPF by a specialist ILD multidisciplinary team according to 
international guidelines,1 and excluded those with co-morbidities that would make exercise unsafe 
(e.g. unstable ischemic heart disease).  All participants provided informed written consent and the 
studies were approved by the London-Riverside Research Ethics Committee (14/LO/2248, 
14/LO/2247, 15/LO/0015) and registered on clinicaltrials.gov (NCT02445157, NCT02436278, 
NCT02530736). 
 
Measurements 
 
4MGS was measured on a flat, 4-metre course with a standing start with patients walking at their 
usual speed as previously described.10 The assessment was undertaken by trained research staff 
and physiotherapy assistants who followed a standard operating procedure. Two tests were 
performed with minimal rest and the faster of the two, measured by stopwatch, was used to 
calculate gait speed. Further details are available at www.healthmeasures.net.  
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Pulmonary function tests included spirometry (forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC)) and diffusion capacity for carbon monoxide (DLCO) (Jaeger Master 
screen PFT, Carefusion Ltd., UK).21 The composite physiologic index (CPI)22 and the gender, age 
and physiology (GAP) index, a prognostic staging system23 were calculated as previously 
described.  High resolution Computed Tomography (HRCT) scans were obtained using a 64-slice 
multiple detector scanner (Somatom Sensation 64, Siemens, Germany) and visually scored by two 
sub-specialist, experienced, thoracic radiologists (DMH, JJ) for the extent of ILD (to the nearest 
5%) as described previously.24 The six minute walk distance (6MWD) was conducted on a 30-
metre course according to the international guidelines.25 The incremental shuttle walk (ISW) was 
conducted on a 10-metre course, as previously described.26 Health status was measured using the 
King's Brief Interstitial Lung Disease (KBILD) questionnaire.27 The Medical Research Council 
Dyspnoea scale (MRC)28 was used to assess dyspnoea and respiratory disability, whilst co-
morbidity burden was quantified using the age-adjusted Charlson Co-morbidity Index.29  
 
Reliability, validity and stratification  
  
To evaluate test-retest and inter-observer reliability, participants performed the 4MGS test on two 
separate occasions 7-14 days apart in a clinic consultation room. On the first occasion, two 
observers measured 4MGS simultaneously.    
The concurrent validity of 4MGS was assessed using a prospective study comprising two 
independent cohorts. The main cohort was recruited from a specialist ILD clinic at the Royal 
Brompton Hospital. Measurements included 4MGS, pulmonary function tests (calculated CPI and 
GAP index), HRCT, 6MWD, KBILD and MRC. A second validation cohort was recruited from 
an ambulatory oxygen assessment clinic; patients underwent 4MGS, spirometry, 6MWD, and 
MRC. 
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Patients in the main cohort were stratified according to the gait speed prognostic cut-point 
recommended by expert consensus groups (slow gait speed: <0.8ms-1; preserved gait speed: 
≥0.8ms-1),11, 12 and differences in phenotypic characteristics compared between groups.  
 
Response to Pulmonary Rehabilitation 
 
IPF patients were prospectively recruited from the Harefield PR Unit, UK and underwent a 
multidisciplinary, outpatient 8-week PR programme as previously described.30  4MGS, MRC, 
ISW, and KBILD were recorded before and after the programme. 
 
Statistical analysis 
 
For the reliability analysis, assuming a 5% significance level and 80% power with two 
observations, a minimum of 39 patients would be needed to show an intra-class correlation co-
efficient (ICC) >0.6 when the true coefficient is 0.8.31  For the validity study, to demonstrate a 
moderate strength correlation (r>0.4) between 4MGS and 6MWD against the null hypothesis (r=0) 
with 90% power at a p-value threshold of 0.05 would require a minimum of 62 patients. For the 
responsiveness study, previous data indicated that the difference in the response of matched pairs 
is normally distributed with a standard deviation of 0.13ms-1.13  If the true difference in the mean 
response of matched pairs is 0.08ms-1, a minimum 30 pairs of patients would be needed with 90% 
power at 5% significance level to reject the null hypothesis that this response difference is zero. 
Data analyses were performed using GraphPad Prism 6 (GraphPad Software, USA) and SPSS 
version 22 (IBM, USA). Single measure ICCs of consistency and random effect were calculated 
with 95% confidence intervals (95%CI) to examine inter-observer and test-retest reliability. 
Measurement variability was determined by calculating the standard error of measurement (SEM) 
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and percentages of SEM (SEM%).  Bland–Altman plots were plotted to demonstrate the 95% 
limits of agreement. Pearson’s correlation co-efficient (Spearman’s rank for non-parametric data) 
was used to quantify the correlation between 4MGS and other measures. Multivariable regression 
was used to investigate determinants of 4MGS. 6MWD, MRC, GAP index, FVC %predicted, body 
mass index, age-adjusted Charlson Co-morbidity Index and KBILD-T were considered as 
independent variables.  Age, sex and DLCO %predicted were not considered as they are 
components of the GAP index.  After checking for co-linearity between independent variables 
(r < 0.5), a stepwise approach was used to retain or remove them from the model; entry criterion 
p < 0.05, removal criterion p ≥ 0.10. Between-group differences were assessed using unpaired t-
tests (Mann Whitney U test for nonparametric data). Paired t-tests (Wilcoxon Signed Rank test for 
nonparametric data) were used to compare outcomes before and after PR and the effect size was 
calculated using Cohen’s d. Statistical significance was considered to be p<0.05. 
RESULTS  
 
Reliability  
 
Sixty patients were approached: 13 declined to participate and one did not meet the inclusion 
criteria.  The baseline characteristics of the recruited 46 patients were: 33 (72%) male; mean 
(standard deviation) age 75 (7.6) years; body mass index 27.1 (5.8)kg/m2; 4MGS 0.94 (0.25)ms-1; 
FVC 71.9 (20.8)%predicted; DLCO 47.4 (21.3)%predicted. 
4MGS showed high inter-observer and test-retest reliability with ICC values (95%CI) of 0.996 
(0.992 to 0.998) and 0.983 (0.970 to 0.991) respectively.  The mean differences between test 
occasions and observers were 0.001ms-1 and 0.01ms-1 respectively with no significant change in 
gait speed between the two occasions (p=0.85) or between observer values (p=0.42).  Measurement 
variability was low with SEM and SEM% values of 0.002 and 0.16% for inter-observer and 0.0002 
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and 0.65% for test-retest reliability respectively.  Narrow limits of agreement between observers 
(0.05 to -0.04) and occasions (0.09 to -0.09) were demonstrated in the Bland Altman plots.   
 
Validity and stratification  
 
For the main cohort, we approached 87 patients: 17 declined to participate and five did not meet 
the inclusion criteria.  The baseline characteristics of the 65 recruited patients and the relationship 
between 4MGS and other outcome measures are reported in Table 1. Seven patients used a walking 
aid whilst seven other patients were prescribed ambulatory oxygen. 4MGS was strongly correlated 
with 6MWD (r=0.76, p<0.001), and had a moderately strong relationship with health status, 
(KBILD total: r=0.44, p=0.0003), and a negative correlation with MRC (r=-0.56, p<0.0001) and 
GAP index (r=-0.41; p=0.002). No significant relationships were seen between 4MGS and HRCT 
extent of disease, nor with lung function parameters such as FVC or DLCO %predicted.  
The independent validation cohort (n=62) undergoing ambulatory oxygen assessment had the 
following baseline characteristics: 46 (74%) men; mean (standard deviation) age 74 (8) years; FVC 
69 (22)%predicted; 4MGS 0.87 (0.25)ms-1; MRC 3(1); 6MWD 229 (103)m; ISW 246 (131)m.  
Similar to the main cohort, 4MGS correlated strongly with 6MWD (r=0.85, p<0.0001), and 
negatively with MRC (r=-0.59, p=0.0002).  
Using a stepwise multivariable linear regression model to describe 4MGS, 6MWD alone explains 
57% of the variance in 4MGS (Table 3, Model 1). However the addition of GAP index explained 
67% of the variance in 4MGS (Table 3, Model 3). The equation to predict 4MGS is: mean (95% 
confidence interval) 4MGS = 0.001 (0.001 to 0.002) * 6MWT -0.040 (-0.078 to -0.002) * GAP 
index + 0.586 (0.356 to 0.817) ms-1, r2=0.67, p<0.0001. 
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In the main cohort, 24 (37%) participants had a “slow 4MGS” and 63% had preserved 4MGS. 
Those with slow 4MGS were older, but there were no differences in sex distribution, lung function 
parameters or radiological quantification of ILD. However large deficits in exercise capacity, 
respiratory disability, health status and multi-dimensional prognostic index were observed in the 
slow 4MGS group (Table 2 and Figure 1). For example, there was a mean (95%CI) 6MWD 
difference of 167 (133 to 220)m between the slow and preserved gait speed groups.  
Response to Pulmonary Rehabilitation 
 
Of 79 IPF patients referred to the Harefield PR Unit, nine declined to participate, three did not 
meet the inclusion criteria, and seven failed to complete PR. The baseline characteristics and 
response to PR of these patients are in Table 4.  4MGS was strongly correlated with ISW (r=0.74; 
p=<0.0001). Mean (95%CI) change in 4MGS was 0.16 (0.12 to 0.20)ms-1 with effect size of 0.65.  
There was no significant correlation between change in and baseline 4MGS (r=-0.23; p=0.08).   
DISCUSSION 
 
This study determines the reliability, validity and responsiveness of 4MGS in an IPF-specific 
population. We demonstrated high inter-observer and test-retest reliability and in two independent 
cohorts, 4MGS correlated strongly with 6MWD (the best characterised field walking test in IPF) 
and moderately with measures of dyspnoea, health status and a multi-dimension prognostic index.  
When used to stratify participants according to slow gait speed, 4MGS could identify differences 
in phenotypic characteristics such as exercise capacity, health status, dyspnoea and prognosis 
index despite similar lung function and radiological parameters.  We propose 4MGS has potential 
as a simple tool in the assessment and stratification of patients with IPF. 
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There is a paucity of data on 4MGS in this population. In earlier work, DePew et al studied 70 
people with chronic lung disease (n=55 ILD – IPF data not reported) and demonstrated, like our 
study, a strong correlation between 4MGS and 6MWD (r=0.70) and a significant negative 
correlation with MRC (r=-0.44) in the whole group.16 Mendes et al measured the short physical 
performance battery (SPPB) (a component of which is usual gait speed measured over 2.4 metres) 
in 26 advanced ILD patients (n=23 IPF) listed for lung transplantation, and demonstrated lower 
SPPB scores compared with 12 age-matched controls.17 Absolute gait speed values were not 
reported, and the relationship between gait speed and measures of functional status were not 
presented. Furthermore, 2.4 metres may not be sufficiently long to ensure measurement accuracy19 
and has worse test-retest reliability compared to using 4 metres.20  In a study involving 52 ILD 
patients (n=20 IPF), Ryerson et al reported a weak but significant relationship between gait speed 
and measures of dyspnoea (Baseline Dyspnoea Index: r=-0.36; University of California San Diego 
Shortness of Breath Questionnaire: r=0.37).32 They also showed figuratively that 4MGS improved 
with a 6 to 9 week outpatient PR programme in 54 ILD patients (n=22 IPF) (p=0.01), but neither 
absolute values nor effect size were reported leading to difficulty with data interpretation.18   To 
our knowledge, our study is the first to report the reliability of 4MGS, provide evidence to support 
its validity as a measure of functional status, and demonstrate its responsiveness to PR in 
adequately powered IPF-specific cohorts. 
There are some limitations to 4MGS and our study. First, there is a recognised “ceiling effect” 
associated with 4MGS,13 and therefore it may have more value as an outcome or stratification tool 
in poorly functioning individuals than in those with well-preserved functional status. Second, 
4MGS is not a measure of peak exercise capacity,33 but an indicator of functional impairment, 
particularly in frail older patients, and has been previously used as a functional outcome measure 
in interventional pharmacological trials.34  Third, as the study participants were primarily 
outpatients attending specialist ILD clinics at a tertiary centre, our data need to be corroborated in 
13 
 
other IPF populations and settings. Fourth, we were unable to comment on the longitudinal validity 
of 4MGS in IPF, particularly with regards to prognostic value.  Given the prognostic value of the 
6MWD and the GAP index in IPF, and the relationships observed between 4MGS and these 
prognostic indices in our study, we hypothesise that 4MGS will help predict mortality in IPF, as 
has been consistently observed in community-dwelling elders.12  Future longitudinal studies are 
required to confirm this hypothesis. Fifth, 4MGS showed no relationship with lung function or 
HRCT parameters, which arguably are a more precise reflection of lung disease severity.  
Therefore we do not envisage a role for 4MGS as a primary outcome measure in trials of anti-
fibrotic drugs, but it may have value in stratifying IPF patients. We demonstrated that the “slow 
gait speed” clinical phenotype exhibited significantly reduced exercise capacity, increased 
dyspnoea and poor health status in comparison to those with preserved gait speed. However, 
despite large differences between slow and preserved gait speed groups, there was no significant 
difference in lung function or HRCT results, suggesting that extra-pulmonary factors such as 
ageing, skeletal muscle manifestations, and frailty35, 36 may contribute significantly to morbidity 
and perhaps prognosis. This is corroborated by data from a recent trial of anti-fibrotic medication 
that showed little impact on health status.37 
 
4MGS has several attractive properties. It is cheap and quick to perform, and requires little space. 
As walking is familiar to the vast majority of adults, the test is easy to understand and has been 
shown to be reliable even in people with cognitive dysfunction.38  These properties mean that 
4MGS could be adopted in almost any clinical environment including the home19 or hospital 
bedside.9  We believe that 4MGS may play a particular role in measuring functional performance 
in advanced IPF when measuring exercise capacity with field walking tests like the 6MWTmight 
become less acceptable to patients with severe ventilatory limitation or dyspnoea,39 leading to 
missing data in research and clinical settings.  Additionally, the 6MWT requires a 30 metre course 
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which may limit its applicability in many settings compared to 4MGS..  In this study, we 
demonstrated that 4MGS was responsive to PR, and as responsive as the ISW, an established field 
walking test widely used by the PR community.13  However, future research is needed to evaluate 
the feasibility and potential function of longitudinal measurements of 4MGS.  
 
Conclusion 
 
4MGS, a simple functional performance measure used in gerontology, is reliable, valid and 
responsive in IPF. Compared to those with preserved gait speed, the “slow gait speed” phenotype 
is characterised by significantly reduced exercise capacity, increased dyspnoea and impaired 
health status despite comparable lung function and HRCT abnormalities. 
  
15 
 
ACKNOWLEDGEMENTS 
 
Guarantor: Dr. William Man is the guarantor of the content of the manuscript, including the 
data and analysis. 
Author contributions:  Substantial contributions to the conception and design of the study: 
WD-CM1,2, CMN1,2,  MM3, TMM4,5, PC7; substantial contribution to the acquisition of Data: 
CMN1,2, SEJ1,  REB1, SP1; Analysis and interpretation of the data: CMN1,2, MM3, TMM4,5, JJ6, 
DMH6, PC7, WD-CM1,2; First draft of the manuscript: CMN1,2, MM3, WD-CM1,2; Revision of 
the manuscript critically for important intellectual content: All authors; Approval of the final 
manuscript: All authors; Accountability for all aspects of the work: CMN1,2, WD-CM1,2. 
Author affiliations:  
1. Harefield Pulmonary Rehabilitation and Muscle Research Group, Royal Brompton & 
Harefield NHS Foundation Trust, UK 
2. National Heart and Lung Institute, Imperial College London, UK 
3. King’s College London, Cicely Saunders Institute, Division of Palliative Care, Policy & 
Rehabilitation, London, UK 
4. Interstitial Lung Disease Unit, Royal Brompton & Harefield NHS Foundation Trust, UK 
5. Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, 
UK. 
6. Department of Radiology, Royal Brompton & Harefield NHS Foundation Trust, UK 
7. Department of Occupational and Environmental Medicine, Imperial College London, UK 
 
Financial/nonfinancial disclosures: CMN is supported by a National Institute for Health 
(NIHR) Doctoral Research Fellowship (DRF-2014-07-089). MM is supported by Cicely 
Saunders International and NIHR CLAHRC for South London. TMM is supported by an NIHR 
Clinician Scientist Fellowship (NIHR Ref: CS-2013-13-017). REB and SP are funded by the 
NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation 
Trust and Imperial College. JJ is funded by the Royal Brompton and Harefield NHS Foundation 
Trust. DMH is the recipient of a NIHR Senior Investigator Award. PC is funded by Imperial 
16 
 
College London. WD-CM is part funded by the NIHR CLAHRC for NW London as well as by a 
NIHR Clinical Scientist award (CS/7/007), NIHR Clinical Trials Fellowship (NIHR-CTF-01-12-
04) and Medical Research Council (MRC) New Investigator Grant (G1002113).  The views 
expressed in this publication are those of the authors and not necessarily those of the NHS, the 
NIHR nor the Department of Health. 
Funding source:  The National Institute for Health Research supported CMN financially 
through a Doctoral Research Fellowship (DRF-2014-07-089) but had no role in the development 
of the research and manuscript. 
Other: The authors are grateful for the support of the staff of the Harefield Pulmonary 
Rehabilitation and Research Team and the Interstitial Lung Disease Unit at the Royal Brompton 
and Harefield NHS Foundation Trust. We would particularly like to thank the patients for their 
participation in this study. 
 
REFERENCES 50 ALLOWED – all at the end of the manuscript – will rearrange when 
text has been amended. 
  
17 
 
TABLES 
TABLE 1: Baseline characteristics and relationship (r value) between 4MGS and other outcome 
measures in the first validity cohort (n=65) 
Data are reported as mean (standard deviation) and r value (95% confidence interval) unless 
stated otherwise 
Abbreviations: MRC: Medical Respiratory Council Dyspnoea score; BMI: Body Mass Index; 
Charlson: Charlson Co-morbidity index; FVC: Forced Vital Capacity; FEV1/FVC: ratio of 
Variable (n=65) Baseline  r value p value 
Sex (male: n (%)) 58 (89) - - 
Age (years) 72 (7) -0.35 (-0.54 to -0.11) 0.0049 
MRC 3 (1) -0.56 (-0.71 to -0.36) <0.0001 
BMI (kg/m2) 27.3 (4.4) -0.01 (-0.26 to 0.23) 0.91 
Age-adjusted Charlson 
Co-morbidity Index 
0 (0, 5) -0.13 (-0.37 to 0.13) 0.31 
FVC (L) 2.6 (0.7) 0.14 (-0.10 to 0.37) 0.25 
FVC (% predicted) 73.2 (16.5) 0.15 (-0.10 to 0.38) 0.24 
FEV1/FVC 81.2 (6.8) 0.12 (-0.13 to 0.35) 0.35 
DLCO (% predicted) 43.8 (14.3) 0.13 (-0.14 to 0.38) 0.35 
CPI  49.7 (10.8) -0.13 (-0.38 to 0.14) 0.35 
GAP index     
   Stage 1 (%) 22 - - 
   Stage 2 (%) 67 - - 
   Stage 3 (%) 11 - - 
GAP score 4 (1) -0.41 (-0.61 to -0.16) 0.002 
4MGS (ms-1) 0.89 (0.25) - - 
6MWD (m) 355 (132) 0.76 (0.63 to 0.85) <0.0001 
KBILD – Psychological 60.4 (22.1) 0.34 (0.11 to 0.54) 0.006 
KBILD – Breathlessness 
and activities 
40.9 (19.2) 0.45 (0.23 to 0.62) 0.0002 
KBILD – Chest symptoms 66.7 (24.0) 0.42 (0.19 to 0.60) 0.0006 
KBILD – Total 56.7 (13.8) 0.44 (0.22 to 0.62) 0.0003 
Total lung ILD extent on 
HRCT (%) 
33.6 (13.6) -0.05 (-0.30 to 0.21) 0.71 
18 
 
Forced Expiratory Volume in 1 second and Forced Vital Capacity; DLCO: Diffusing Capacity for 
Carbon Monoxide; CPI: Composite Physiologic Index; GAP: Gender, Age and Pulmonary 
Function index; 4MGS: 4 Metre Gait Speed; 6MWD: 6 Minute Walking Test distance; KBILD: 
King’s Brief Interstitial Lung Disease questionnaire; HRCT: High resolution computed 
tomography 
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TABLE 2: Phenotypic characteristics and between group differences of patients with slow and 
preserved gait speed 
Variable (n=65) 
Slow gait speed 
<0.80ms-1 
(n=24) 
Preserved gait 
speed 
≥0.80ms-1 
(n=41) 
Between group 
difference 
p value 
Sex (male: n (%)) 24 (100) 34 (83) -10 (-17) 0.03 
Age (years) 75 (7) 71 (7) -4 (-8 to -1) 0.02 
MRC  3.4 (1.0) 2.7 (1.0) -0.7 (-0.2 to -0.1) 0.01 
BMI (kg/m2) 27.2 (4.0) 27.3 (4.7) 0.1 (-2.2 to 2.4) 0.91 
Age-adjusted Charlson 
Co-morbidity Index  
0 (0, 5) 2 (0, 5) 2 (0, 2) 0.98 
FVC (L) 2.6 (0.7) 2.6 (0.6) 0.01 (-0.33 to 0.35) 0.95 
FVC (% predicted) 69.0 (14.9) 75.6 (17.0) 6.6 (-1.9 to 15.1) 0.12 
FEV1/FVC 80.4 (8.2) 81.7 (6.0) 1.3 (-2.2 to 4.8) 0.46 
DLCO (% predicted) 44.2 (16.7) 42.5 (14.3) -1.7 (10.4 to 6.9) 0.69 
CPI  50.4 (12.9) 49.3 (9.6) -1.1 (-7.3 to 5.1) 0.73 
GAP index 5 (1) 4 (1) -0.8 (-1.4 to -0.2) 0.01 
4MGS (ms-1) 0.64 (0.13) 1.04 (0.17) 0.40 (0.32 to 0.48) <0.0001 
6MWD (m) 250 (92) 416 (112) 167 (133 to 220) <0.0001 
KBILD - Psychological 52.7 (16.0) 65.0 (23.9) 12.3 (1.2 to 23.3) 0.03 
KBILD – 
Breathlessness and 
activities 
32.1 (16.0) 46.2 (19.2) 14.1 (4.8 to 23.5) 0.004 
KBILD – Chest 
symptoms 
56.7 (23.2) 72.8 (22.7) 16.1 (4.3 to 27.9) 0.01 
KBILD - Total 50.8 (11.1) 60.2 (14.2) 9.4 (2.6 to 16.2) 0.007 
Total lung ILD extent 
on HRCT (%) 
33.2 (15.4) 33.9 (12.9) 0.7 (-6.9 to 8.2) 0.86 
Data are reported as mean (standard deviation), median (25th, 75th centile), mean (95% 
confidence interval) change or median (25th, 75th centile) change unless stated otherwise 
 Abbreviations: MRC: Medical Respiratory Council Dyspnoea score; BMI: Body Mass Index; 
Charlson: Charlson Co-morbidity index; FVC: Forced Vital Capacity; FEV1/FVC: ratio of 
Forced Expiratory Volume in 1 second and Forced Vital Capacity; DLCO: Diffusing Capacity for 
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Carbon Monoxide; CPI: Composite Physiologic Index; GAP: Gender, Age and lung Physiology; 
4MGS: 4 Metre Gait Speed; 6MWD: 6 Minute Walking Test distance; KBILD: King’s Brief 
Interstitial Lung Disease questionnaire; HRCT: High resolution computed tomography. 
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TABLE 3: Multivariable linear regression models to predict 4MGS 
 
Model Covariate β co-efficient (95% CI) p-value Model r2 (adjusted r2) 
I 6MWD 0.001 (0.001 to 0.002) <0.0001 0.58 (0.57) 
     
II 
6MWD 0.001 (0.001 to 0.002) <0.0001 
0.59 (0.58) 
MRC -0.038 (-0.088 to 0.011) 0.13 
     
III 
6MWD 0.001 (0.001 to 0.002) <0.0001 
0.67 (0.66) GAP index -0.040 (-0.078 to -
0.002) 
0.04 
 
Abbreviations: 6MWD: 6 Minute Walking Test distance, MRC: Medical Research Council 
Dyspnoea score, GAP: Gender, Age and lung Physiology; CI: Confidence Interval 
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TABLE 4: Baseline characteristics and response to pulmonary rehabilitation 
 
 
 
 
 
 
 
 
Variable (n=60) Baseline characteristics Change following PR p value 
Sex (male) (n (%)) 43 (72) - - 
Age (years) 74 (69, 79) - - 
MRC  3 (1) -0.7 (-0.5 to -0.9) <0.001 
BMI (kg/m2) 27.7 (4.5) 0.1 (-0.5 to 0.6) 0.94 
Age-adjusted Charlson  4 (0, 4) - - 
FVC (%) 75 (21) 0.8 (-1.2, 2.8) 0.41 
Walking aid (n (%)) - - - 
   Walking stick 1 (2) - - 
LTOT (n (%)) 4 (7) - - 
ABOT (n (%)) 8 (13) - - 
Pirfenidone (n (%)) 7 (12) - - 
Nintedanib (n (%) 0 (0) - - 
4MGS (ms-1) 0.95 (0.24) 0.16 (0.12 to 0.20) <0.001 
ISW (m) 296 (184) 50 (10, 80) <0.001 
KBILD-Psychological 62.1 (17.8) 6.0 (1.9 to 10.1) <0.01 
KBILD-Breathlessness 
and activities 
41.9 (35.6, 52.5) 6.1 (0.01, 12.6) <0.01 
KBILD-Chest 
symptoms 
69.2 (18.8) 4.6 (-1.0, 10.3) 0.11 
KBILD-Total 58.3 (10.9) 4.6 (3.7 to 2.1) <0.001 
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Data are reported as mean (standard deviation), median (25th, 75th centile), mean (95% 
confidence interval) change or median (25th, 75th centile) change unless stated otherwise 
Abbreviations: MRC: Medical Respiratory Council Dyspnoea Score; BMI: Body Mass Index; 
FVC: Forced Vital Capacity; FEV1/FVC: ratio of Forced Expiratory Volume in 1 second and 
Forced Vital Capacity; LTOT: long-term oxygen therapy; ABOT: ambulatory oxygen therapy; 
4MGS: 4 Metre Gait Speed; ISW: Incremental Shuttle Walk Test; CRQ: Chronic Respiratory 
Questionnaire; KBILD: King’s Brief Interstitial Lung Disease questionnaire. 
 
FIGURE LEGEND 
 
 
 Figure 1: Slow and preserved gait speed in cohort 1 a) 6MWD; b) KBILD T; c) MRC 
Dyspnoea score; d) GAP index 
Abbreviations: 6MWD:6 minute walk distance; KBILD T: King’s Brief Interstitial Lung 
Disease questionnaire – Total score; MRC: Medical Research Council; GAP: Gender, 
Age, Physiology. 
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